StreetInsider.com News Articles

Form 4 iBio, Inc. For: Oct 14 Filed by: Stoner Elizabeth

Thu, 15 Oct 2026 18:34:00 -0400

si-local-file:///var/storage/secattach/20261015/27194412.html

Form 4 iBio, Inc. For: Oct 14 Filed by: Kropotova Alexandra

Thu, 15 Oct 2026 18:33:00 -0400

si-local-file:///var/storage/secattach/20261015/27194409.html

Form 4 iBio, Inc. For: Oct 14 Filed by: Arkowitz David

Thu, 15 Oct 2026 18:32:00 -0400

si-local-file:///var/storage/secattach/20261015/27194408.html

Form 4 iBio, Inc. For: Oct 14 Filed by: Clark William D

Thu, 15 Oct 2026 18:32:00 -0400

si-local-file:///var/storage/secattach/20261015/27194407.html

Form 4 iBio, Inc. For: Oct 14 Filed by: Parada Antonio Bernardino Guimaraes

Thu, 15 Oct 2026 18:31:00 -0400

si-local-file:///var/storage/secattach/20261015/27194406.html

Form 4 iBio, Inc. For: Oct 14 Filed by: Sender Gary

Thu, 15 Oct 2026 18:30:00 -0400

si-local-file:///var/storage/secattach/20261015/27194404.html

Form SCHEDULE 13G iBio, Inc. Filed by: Coastlands Capital LP

Wed, 14 Oct 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20261014/27186020.html

Form 8-K iBio, Inc. For: Oct 13

Tue, 13 Oct 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20261013/27177762.html

iBio reports IBIO-610 muscle-preservation data from primate study

Tue, 13 Oct 2026 07:04:22 -0400

iBio, Inc. (NASDAQ: IBIO) shared preclinical body-composition data from a non-human primate (NHP) study evaluating IBIO-610, an Activin E antibody candidate, alone and in combination with semaglutide, a GLP-1 receptor agonist used to treat obesity. The data were presented at the European Association for the Study of Diabetes Annual Meeting on Oct. 1, 2026.

In the eight-week obese NHP study, with six animals per group, fat accounted for 93% of weight lost in primates given a single dose of IBIO-610 alongside twice-weekly semaglutide, compared with 77% for those given semaglutide alone. Expressed differently, lean mass made up 6% of weight lost

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

Tue, 13 Oct 2026 07:00:00 -0400

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone

iBio expects to start first-in-human trials of IBIO-610 in first half of 2027

SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate, alone and in combination with semaglutide,

iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy

Tue, 13 Oct 2026 07:00:00 -0400

In an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone

iBio expects to start first-in-human trials of IBIO-610 in first half of 2027

H.C. Wainwright Starts iBio, Inc. (IBIO) at Buy

Thu, 17 Sep 2026 06:53:35 -0400

(Updated - September 17, 2026 6:53 AM EDT)

H.C. Wainwright analyst Ananda Baruah initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Buy rating and a price target of $7.00.

The analyst comments "We initiate iBio (IBIO) with a Buy and a $7 price target. We believe IBIO-610's Activin E antibody looks promising given the preclinical and especially NHP data and the convergent human data from Arrowhead, Wave and BaseCure on visceral fat, liver fat and lean mass, addressing a next-generation obesity/T2D/MASH need in a $150-200B market still under penetrated for incretins. We think having consensus across different trials is a strong

H.C. Wainwright Starts iBio, Inc. (IBIO) at Buy

Thu, 17 Sep 2026 06:53:35 -0400

(Updated - September 17, 2026 6:53 AM EDT)

H.C. Wainwright analyst Ananda Baruah initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Buy rating and a price target of $7.00.

B.Riley Starts iBio, Inc. (IBIO) at Buy

Tue, 15 Sep 2026 05:02:24 -0400

B.Riley analyst Madison El-Saadi initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Buy rating and a price target of $11.00.

The analyst comments "We are transferring coverage of Orchestra BioMed Holdings, Inc. (OBIO) with a Buy rating and raising our PT from $10 to $11, reflecting conviction in BACKBEAT Ph3 topline (2Q27) and OBIO's high-margin royalty-based model we think harbors underappreciated FCF potential. OBIO partners with large medical-device companies to fund development and scale commercialization, a model differentiated among peers. Its lead asset, AVIM Therapy, lowers blood pressure through a software update to dualchamber pacemakers, and could launch by mid-28.

B.Riley Starts iBio, Inc. (IBIO) at Buy

Tue, 15 Sep 2026 05:02:24 -0400

B.Riley analyst Madison El-Saadi initiates coverage on iBio, Inc. (NASDAQ: IBIO) with a Buy rating and a price target of $11.00.

Form 8-K iBio, Inc. For: Sep 14

Mon, 14 Sep 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260914/27058648.html

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

Tue, 01 Sep 2026 16:30:00 -0400

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston.

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET.

A livestream of the event can be accessed here, and a replay of the presentation webcast

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

Tue, 01 Sep 2026 16:30:00 -0400

Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET.

A livestream of the event can be accessed here, and a replay of the presentation webcast

Form 10-K iBio, Inc. For: Jun 30

Fri, 28 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26993379.html

Form 10-K iBio, Inc. For: Jun 30

Fri, 28 Aug 2026 08:33:00 -0400

si-local-file:///var/storage/secattach/20260828/26993379.html

Form 8-K iBio, Inc. For: Aug 28

Fri, 28 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26993364.html

Form 8-K iBio, Inc. For: Aug 28

Fri, 28 Aug 2026 08:31:00 -0400

si-local-file:///var/storage/secattach/20260828/26993364.html

iBio posts $33M net loss in fiscal 2026 as R&D spending surges

Fri, 28 Aug 2026 07:02:09 -0400

iBio, Inc. (NASDAQ: IBIO) reported a net loss of $33.0 million for the fiscal year ended June 30, 2026, compared with a net loss of $18.4 million in the prior year, according to a company press release.

Revenue fell to approximately $0.1 million from $0.4 million in fiscal 2025. Research and development expenses rose to $19.6 million from $8.3 million, an increase of approximately $11.3 million, driven largely by spending on consultants and outside services for the IBIO-610 and IBIO-600 programs and a $2.5 million development milestone. General and administrative expenses were roughly flat at $10.6 million. The company also recorded

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Fri, 28 Aug 2026 07:00:00 -0400

SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.

“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

Fri, 28 Aug 2026 07:00:00 -0400